45 results about "Bbb permeability" patented technology

The present invention relates to a method of increasing blood brain barrier ("BBB") permeability in a subject. This method involves administering to the subject an agent or agents which activate both of the A1 and A2A adenosine receptors. Also disclosed is a method to decrease BBB permeability in a subject. This method includes administering to the subject an agent which inhibits or blocks the A2A adenosine receptor signaling. Compositions relating to the same are also disclosed.

Disclosed herein is a method of facilitating the delivery of an agent across blood-brain barrier (BBB) of a subject. The method includes administering to the subject in sequence or concomitantly, an effective amount of a growth factor selected from the group consisting of, vascular endothelial growth factor (VEGF), insulin-like growth factor I (IGF-1), IGF-II, a portion thereof and a combination thereof; and an agent that is any of a therapeutic agent or an imaging agent. The administered amount of the growth factor is capable of transiently increasing BBB permeability of the subject and thereby allowing the agent to be delivered across BBB. Also disclosed herein is a method of treating a subject suffering from a brain tumor, a brain stroke, a neuropsychiatric disorder and / or a neurodegenerative disease.

The invention discloses the application of apolipoprotein E receptor mimic peptide 6KApoEp in the preparation of drugs for treating secondary brain injury after cerebral hemorrhage, and discloses the protein sequence of apolipoprotein E receptor mimic peptide 6KapoEp, apolipoprotein E receptor The construction method of the protein sequence of the analog peptide 6KapoEp, and the preparation of the application mixture, after the application of 6KApoEp, the expression of CypA can be reduced, and the cerebral edema and blood-brain barrier damage and inflammation after cerebral hemorrhage can be alleviated by inhibiting the activation of the MMP-9 pathway Factor production; reduce brain water content, improve BBB permeability, promote the increase of blood-brain barrier-related proteins such as claudin-5, occludin, ZO-1, regulate cerebral hemorrhage by inhibiting CypA / NF-KB / MMP-9 Post-inflammatory response, reduce brain tissue water content, improve blood-brain barrier permeability, thereby reducing secondary brain damage after cerebral hemorrhage, play a neuroprotective role in cerebral hemorrhage, reduce post-cerebral hemorrhage inflammatory response, improve blood-brain barrier permeability permeability effect.

The present invention relates to a novel serine derivative compound having improved blood-brain barrier (BBB) permeability, and a use of same, and more specifically, to a novel serine derivative compound having further improved BBB permeability compared to L-serine, and a pharmaceutical composition comprising the compound as an effective compound for preventing or treating / alleviating central nervous system diseases, such as cognitive disorders, intellectual disabilities, microcephaly, epilepsy, neurodevelopmental disorders, dementia, autism spectrum disorders, Down syndrome, Rett syndrome, fragile X syndrome, Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis. A compound of chemical formula (I) or a pharmaceutically acceptable salt thereof asan effective component for the pharmaceutical composition of the present invention for preventing or treating central nervous system diseases exhibits significantly improved BBB permeability comparedto L-serine, and activates the propagation of neurons, and through the neuroprotective effect that inhibits oxidative stress-induced mitochondrial membrane potential disruption and / or endoplasmic reticulum stress-induced apoptotic neuronal cell death, exhibits desirable effects in the prevention, treatment, and alleviation of central nervous system diseases, such as cognitive disorders, intellectual disabilities, microcephaly, epilepsy, neurodevelopmental disorders, dementia, autism spectrum disorders, Down syndrome, Rett syndrome, fragile X syndrome, Alzheimer's disease, Parkinson's disease,Huntington's disease, and amyotrophic lateral sclerosis. Thus, the compound is an extremely useful invention in the drug industry, food industry, and livestock industry.